← Russell 3000 cross-section

ELV Elevance Health, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-07-15, not restated
Financials

Scale

Market cap
$86.7bn
Revenue TTM
$201.1bn
Net income TTM
$5.0bn
Free cash flow
$6.3bn
Composite score
42.7
Sector rank
#148

Valuation

P / E
17.5
EV / EBITDA
11.7
EV / sales
0.4
FCF yield
7.25%
Earnings yield vs 10-yr
0.99pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
2.5%
EBITDA margin
3.5%
ROE
11.1%
ROIC
13.8%
Revenue growth
6.3%

Insider activity, last 90 days

Net open-market
$1.16m
Buyers
2
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Medicaid cost trends remain elevated due to higher population acuity and increased utilization of services. This was driven by attrition in Medicaid membership, primarily as a result of eligibility redeterminations, and decreases in our Medicare Advantage, Employer Group Risk-Based and FEP ® businesses. These decreases were partially offset by increases in our Employer Group Fee-Based business. Operating revenue for the three months ended June 30, 2026 was $49,826, an increase of $405, or 0.8%, from the three months ended June 30, 2025. Operating revenue for the six months ended June 30, 2026 was $99,320, an increase of $1,134, or 1.2%, from the six months ended June 30, 2025. …Elevance Health, Inc., 10-Q, period ended 2026-06-30, filed 2026-07-15

Read the full passage →